At Rockefeller University, researchers have uncovered how a single protein, MLL4, can simultaneously accelerate leukemia and suppress solid tumors — a paradox that has long confounded cancer biology. Through high-resolution structural imaging, the team discovered that MLL4 operates through two distinct mechanisms: its known role in chemically marking histones, and a newly revealed direct partnership with p53, the cell's foremost guardian against uncontrolled growth. This duality suggests that the same molecular machinery can serve opposing biological purposes depending on cellular context, a r
News-Medical
· Jul 14, 2026
· health
· 3 min de leitura
High
Apuração: Verificado
Structural study reveals MLL4's dual cancer role as both driver and suppressor
◉
Health & Medicine
5898 artigos relacionados
Uganda declares victory over Ebola as last patient discharged
BBC News · 100% correspondência
Experimental drug shows early promise for treatment-resistant prostate…
Medical Xpress · 99% correspondência
Should low-risk tumors still be called cancer?
The Irish Times · 99% correspondência
WHO warns cancer kills 26,000 daily as Nigeria expands patient support
The Guardian Nigeria News · 99% correspondência
DRC launches record-pace Ebola drug trial as first patients enrolled
The Guardian · 99% correspondência
Cobertura Relacionada
Google News · Jul 17
Cyclosporiasis Outbreak Spreads Across U.S.: What You Need to Know
A multi-state cyclosporiasis outbreak is causing diarrheal illness across the US. Health experts advise on symptoms, foo…
The Guardian · Jul 17 Oxford study finds salsa dancing reduces depression and anxiety in young adultsA randomized controlled trial by Oxford researchers found that eight-week salsa classes reduced depressive symptoms and …
NZ Herald · Jul 17 Gisborne chicken owner weighs bird flu risks against free-range farmingNew Zealand authorities are preparing for potential H5 bird flu arrival, with vaccination programs underway for endanger…
The Transmitter · Jul 17 BCIs unlock secrets of how the brain plans and produces speechLong-term brain implants in patients with epilepsy and ALS are enabling researchers to study how the brain plans and exe…
Impacto Geopolítico
🌎
Rockefeller researchers reveal MLL4 protein's paradoxical cancer role, but this is a basic science discovery with no direct geopolitical implications.
Escalation Risk
low
Confidence
HIGH
Viés e Enquadramento
⚖
Article presents scientific findings neutrally with appropriate expert attribution, though lacks discussion of clinical implications or alternative interpretations of the research.
Bias Direction
center
Confidence
MED
Scientific authority framing - relies heavily on credentialing (Rockefeller University, Robert Roeder as 'pioneer') and peer-reviewed publication (Molecular Cell) to establish legitimacy. Frames MLL4 as 'enigma' and 'special' to emphasize research significance.
unassuming name
quite special
compelling enigma
surprising new characteristics
guardian of the genome
Perspectives from other research groups studying MLL4 or competing theories
Discussion of practical clinical applications or timeline to therapeutic use
Limitations of the structural study or alternative explanations for findings
Patient or clinician perspectives on relevance to treatment
Potential funding sources or conflicts of interest
Lente Econômica
📈
Rockefeller researchers reveal MLL4 protein's paradoxical cancer role, driving leukemia while suppressing solid tumors through p53 cooperation, with implications for targeted cancer therapeutics development.
Market Signal
bullish
Confidence
MED
Pharmaceutical and Biotechnology
Medical Devices and Diagnostics
Healthcare and Hospital Services
Research and Development
Potential future development of more targeted cancer treatments with fewer side effects. Patients with leukemia and solid tumors may benefit from therapies specifically designed around MLL4 mechanisms, though clinical applications remain years away.
FDA may need to establish new regulatory pathways for epigenetic modifier-based therapies. Research funding agencies may prioritize MLL family protein studies. Patent offices may see increased filings for MLL4-targeted therapeutics, influencing biotech IP landscape.